HM Payson & Co. Sells 2,262 Shares of Baxter International Inc (BAX)

HM Payson & Co. cut its holdings in shares of Baxter International Inc (NYSE:BAX) by 4.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,180 shares of the medical instruments supplier’s stock after selling 2,262 shares during the period. HM Payson & Co.’s holdings in Baxter International were worth $3,945,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. First Hawaiian Bank purchased a new position in Baxter International during the third quarter worth about $1,639,000. Retirement Systems of Alabama boosted its holdings in Baxter International by 35.0% during the third quarter. Retirement Systems of Alabama now owns 312,010 shares of the medical instruments supplier’s stock worth $24,053,000 after purchasing an additional 80,919 shares during the last quarter. Natixis boosted its holdings in Baxter International by 62.5% during the second quarter. Natixis now owns 716,411 shares of the medical instruments supplier’s stock worth $52,900,000 after purchasing an additional 275,452 shares during the last quarter. AMP Capital Investors Ltd boosted its holdings in Baxter International by 1.5% during the second quarter. AMP Capital Investors Ltd now owns 267,439 shares of the medical instruments supplier’s stock worth $19,749,000 after purchasing an additional 3,839 shares during the last quarter. Finally, Gulf International Bank UK Ltd boosted its holdings in Baxter International by 2.5% during the third quarter. Gulf International Bank UK Ltd now owns 168,277 shares of the medical instruments supplier’s stock worth $12,972,000 after purchasing an additional 4,175 shares during the last quarter. 81.96% of the stock is owned by institutional investors.

Several research analysts recently weighed in on BAX shares. Argus upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $70.00 price target on the stock in a report on Friday, November 2nd. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a report on Tuesday, September 25th. ValuEngine upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a report on Thursday, November 15th. UBS Group started coverage on shares of Baxter International in a report on Tuesday. They set a “buy” rating and a $80.00 price target on the stock. Finally, Citigroup cut their price target on shares of Baxter International from $76.00 to $69.00 and set a “neutral” rating on the stock in a report on Tuesday, November 13th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $74.18.

In other Baxter International news, SVP Giuseppe Accogli sold 17,647 shares of the business’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $77.27, for a total value of $1,363,583.69. Following the transaction, the senior vice president now directly owns 59,452 shares in the company, valued at $4,593,856.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.05% of the stock is owned by insiders.

BAX opened at $68.55 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.96 and a current ratio of 2.60. The stock has a market capitalization of $36.20 billion, a price-to-earnings ratio of 27.64, a P/E/G ratio of 1.83 and a beta of 1.02. Baxter International Inc has a twelve month low of $61.05 and a twelve month high of $78.38.

Baxter International (NYSE:BAX) last released its earnings results on Wednesday, October 31st. The medical instruments supplier reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.06. The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.79 billion. Baxter International had a net margin of 10.90% and a return on equity of 17.67%. The company’s quarterly revenue was up 2.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.64 earnings per share. As a group, research analysts anticipate that Baxter International Inc will post 3 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 2nd. Shareholders of record on Monday, December 3rd will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 1.11%. The ex-dividend date of this dividend is Friday, November 30th. Baxter International’s payout ratio is 30.65%.

Baxter International announced that its Board of Directors has initiated a share repurchase plan on Tuesday, November 13th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire up to 6.1% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: “HM Payson & Co. Sells 2,262 Shares of Baxter International Inc (BAX)” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.com-unik.info/2018/12/01/hm-payson-co-sells-2262-shares-of-baxter-international-inc-bax.html.

Baxter International Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: Hedge Funds

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit